Cargando…

In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab

BACKGROUND: Eribulin mesylate (eribulin) is a first-in-class halichondrin B-based microtubule dynamics inhibitor. To compare the anti-angiogenic activity of eribulin to that of bevacizumab, we compared tumour vessel remodelling and reoxygenation between the two agents. METHODS: Patients with advance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueda, Shigeto, Saeki, Toshiaki, Takeuchi, Hideki, Shigekawa, Takashi, Yamane, Tomohiko, Kuji, Ichiei, Osaki, Akihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891505/ https://www.ncbi.nlm.nih.gov/pubmed/27140309 http://dx.doi.org/10.1038/bjc.2016.122

Ejemplares similares

Optical Imaging for Monitoring Tumor Oxygenation Response after Initiation of Single-Agent Bevacizumab followed by Cytotoxic Chemotherapy in Breast Cancer Patients
por: Ueda, Shigeto, et al.
Publicado: (2014)

Intracellular hypoxia measured by (18)F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer
por: Asano, Aya, et al.
Publicado: (2018)

Correction to: Intracellular hypoxia measured by F-18 fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen-receptor positive breast (BRCR-D17-00693)
por: Asano, Aya, et al.
Publicado: (2018)

Optical imaging of tumor vascularity associated with proliferation and glucose metabolism in early breast cancer: clinical application of total hemoglobin measurements in the breast
por: Ueda, Shigeto, et al.
Publicado: (2013)

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states
por: Yoshida, T, et al.
Publicado: (2014)

Genomic Profiling Shows Increased Glucose Metabolism in Luminal B Breast Cancer
por: Ueda, Shigeto, et al.
Publicado: (2013)

Clinicopathological and prognostic impact of imaging of breast cancer angiogenesis and hypoxia using diffuse optical spectroscopy
por: Nakamiya, Noriko, et al.
Publicado: (2014)

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer
por: Marmorino, Federica, et al.
Publicado: (2017)

Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration
por: Fan, F, et al.
Publicado: (2011)

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
por: Weickhardt, A J, et al.
Publicado: (2015)

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model
por: Bozec, A, et al.
Publicado: (2008)

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma
por: Jobard, Elodie, et al.
Publicado: (2015)

A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
por: Schiffmann, L M, et al.
Publicado: (2017)

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
por: Goede, V, et al.
Publicado: (2010)

VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
por: Varey, A H R, et al.
Publicado: (2008)

Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety
por: Sugitani, Ikuko, et al.
Publicado: (2017)

Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer
por: Lee, S J, et al.
Publicado: (2014)

In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol
por: Chander, S K, et al.
Publicado: (2007)

In vivo effects of rosiglitazone in a human neuroblastoma xenograft
por: Cellai, I, et al.
Publicado: (2010)

Macrophages promote angiogenesis in human breast tumour spheroids in vivo
por: Bingle, L, et al.
Publicado: (2006)

Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
por: Andersson, Y, et al.
Publicado: (2009)

Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects
por: Ferreira, A K, et al.
Publicado: (2013)

Ffar2 expression regulates leukaemic cell growth in vivo
por: Bindels, Laure B, et al.
Publicado: (2017)

Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo
por: Bright, S A, et al.
Publicado: (2010)

Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo
por: Ewald, J A, et al.
Publicado: (2008)

In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring
por: Zhong, W, et al.
Publicado: (2009)

In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells
por: Jiang, P, et al.
Publicado: (2014)

NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines
por: Yang, Y, et al.
Publicado: (2006)

Antitumour effect of polyoxomolybdates: induction of apoptotic cell death and autophagy in in vitro and in vivo models
por: Ogata, A, et al.
Publicado: (2008)

The hollow fibre assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells
por: Temmink, O H, et al.
Publicado: (2007)

In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin
por: Gyémánt, N, et al.
Publicado: (2010)

The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo
por: Akashi, Y, et al.
Publicado: (2007)

Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo
por: Theys, J, et al.
Publicado: (2006)

The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro
por: Alain, T, et al.
Publicado: (2006)

Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos
por: Farnoushi, Y, et al.
Publicado: (2011)

Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo
por: Arai, E, et al.
Publicado: (2011)

Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)
por: Liu, W M, et al.
Publicado: (2009)

In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours
por: Quintela-Fandino, M, et al.
Publicado: (2013)

Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2018)

Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study
por: Shigekawa, Takashi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5s0irtlrsdv3aega2uk32m92vh